Product
Quadrivalent influenza modRNA vaccine
1 clinical trial
2 indications
Indication
InfluenzaIndication
HumanClinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDERStatus: Completed, Estimated PCD: 2024-03-12